JPRN-UMIN000013451已完成未知
Deferasirox for patients with advanced hepatocellular carcinoma : pilot study - DFX for advanced HCC
Yamaguchi University School of Medicine0 个研究点目标入组 15 人开始时间: 2014年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Severe coexisting illness (expect for chronic hepatitis or liver cirrhosis) 2) Active double cancers 3) Past history of hypersensitivity for drugs including iodine and contrast agent 4) Patients with pregnancy, lactation or possibility of pregnancy 5) Past history of interstitial pneumonia 6) Chronic respiratory failure 7) Patients who judged as inadequacy due to other reasons by the doctor
研究者
相似试验
撤回
2 期
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeMyelodysplastic SyndromesHemochromatosisNCT01892644Haukeland University Hospital
已完成
1 期
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.Hepatic ImpairmentNCT00432627Novartis Pharmaceuticals24
招募中
2 期
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialHepatocellular CarcinomaNCT05886465Sun Yat-sen University40
进行中（未招募）
不适用
Early treatment with deferasirox (Exjade®) in low risk MDS - Exjade-Early-TrialPatients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment.EUCTR2008-006268-12-DEFriedrich-Alexander-Universitaet Erlangen-Nuernberg
进行中（未招募）
不适用
Doxorubicin-Transdrug® in Advanced HepatoCellular CarcinomaA Randomized, Multicenter Phase 2-3 Study. - DOTAHCC1Advanced hepatocarcinoma (HCC)EUCTR2006-004088-77-DEBioAlliance Pharma210